Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Ophthalmol. 2014 Mar;157(3):532-9.e1. doi: 10.1016/j.ajo.2013.11.006. Epub 2013 Nov 13.

Eight-year follow-up of posterior chamber phakic intraocular lens implantation for moderate to high myopia.

Author information

  • 1Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan. Electronic address: iki0478@yahoo.co.jp.
  • 2Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan.

Abstract

PURPOSE:

To assess the long-term clinical outcomes of Implantable Collamer Lens (Visian ICL; STAAR Surgical) implantation for moderate to high myopia.

DESIGN:

Retrospective observational case series.

METHODS:

This study evaluated 41 eyes of 41 patients with myopic refractive errors of -4.00 to -15.25 diopters (D) who underwent ICL implantation and routine postoperative examinations. Before surgery, and 1 and 6 months and 1, 4 and 8 years after surgery, we assessed the safety, efficacy, predictability, stability, and adverse events of the surgery.

RESULTS:

The safety and efficacy indices were 1.13 ± 0.27 and 0.83 ± 0.36. At 8 years, 68.3% and 85.4% of the eyes were within 0.5 and 1.0 D, respectively, of the targeted correction. Manifest refraction changes of -0.32 ± 0.73 D occurred between 1 month and 8 years. The mean endothelial cell loss from preoperative levels was 6.2% at 8 years. Two eyes (4.9%) developed clinically significant symptomatic cataract during the follow-up period. Simultaneous lens extraction and phacoemulsification with IOL implantation was successfully performed in these 2 eyes.

CONCLUSIONS:

According to our experience, ICL implantation was overall good in measures of safety, efficacy, predictability, and stability for the correction of moderate to high myopia during the 8-year observation period, suggesting its long-term viability as a surgical option for the treatment of such eyes.

PMID:
24239774
DOI:
10.1016/j.ajo.2013.11.006
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center